FrancophonIA/ELRC3.0 huggingface dataset:
English: After a number of rounds of replication, genomic instability can reach insupportable levels and result in cancer cell death, as cancer cells already have a high DNA damage load relative to normal cells.
Danish: Efter et antal runder med replikation kan genomisk ustabilitet nå uoverskuelige niveauer og resultere i cancercelledød, da cancerceller allerede har en høj DNA-skadebelastning i forhold til normale celler.
English: Median TSST (months)
Danish: Gennemsnit af TSST (måneder)
English: If MDS and/or AML are confirmed while on treatment with Lynparza, it is recommended that Lynparza should be discontinued and the patient be treated appropriately.
Danish: Hvis MDS og/eller AML diagnosticeres under behandling med Lynparza, anbefales det, at Lynparza seponeres, og patienten får en passende behandling.
English: In the absence of functional BRCA1 or 2, DNA DSBs cannot be repaired via HRR.
Danish: I fravær af funktionelle BRCA1- eller -2-gener kan DNA-dobbeltstrengsbrud ikke repareres via HRR.
English: Number of events: Total number of patients (%)
Danish: Antal hændelser: Samlet antal patienter (%)
English: The incidence of dose interruptions, reductions, discontinuations due to an adverse event was 45.1%, 25.1% and 10.8%, respectively.
Danish: Forekomsten af dosisafbrydelser, -reduktioner og -seponeringer på grund af en bivirkning var henholdsvis 45,1 %, 25,1 % og 10,8 %.
English: • statins, for example simvastatin, pravastatin, rosuvastatin - used to lower blood cholesterol levels
Danish: • statiner, for eksempel simvastatin, pravastatin, rosuvastatin - anvendes til at nedsætte kolesterolniveauet i blodet
English: Genetic counselling for patients with BRCA1/2 mutations should be performed according to local regulations.
Danish: Genetisk rådgivning til patienter med BRCA1/2-mutationer bør udføres ifølge lokale retningslinjer.
English: In the TNBC patient subgroup the confirmed ORR was 48% (41/86) in the olaparib arm and 12% (4/33) in the comparator arm.
Danish: I TNBCpatientsubgruppen blev ORR bekræftet hos 48 % (41/86) i olaparib-armen og (4/33) i komparator-armen.
English: • cyclosporine, sirolimus, tacrolimus - used to suppress the immune system
Danish: • ciclosporin, sirolimus, tacrolimus - anvendes til undertrykkelse af immunsystemet
English: • cisapride - used to treat stomach problems
Danish: • cisaprid - anvendes til behandling af maveproblemer
English: Following oral administration of olaparib via the tablet formulation (2 x 150 mg), absorption is rapid with median peak plasma concentrations typically achieved 1.5 hours after dosing.
Danish: Efter oral administration af olaparib via tabletformuleringen (2 x 150 mg) er absorptionen hurtig, typisk med højeste median plasmakoncentrationer opnået 1,5 timer efter dosering.
English: Co-administration with food slowed the rate (tmax delayed by 2 hours) and marginally increased the extent of absorption of olaparib (AUC increased by approximately 20%).
Danish: Samtidig administration med fødevarer satte hastigheden ned (tmax forsinket med 2 timer) og øgede marginalt omfanget af absorption af olaparib (AUC steg med ca. 20 %).
English: • itraconazole, fluconazole - used for fungal infections
Danish: • itraconazol, fluconazol - anvendes mod svampeinfektioner
English: If patients present with new or worsening respiratory symptoms such as dyspnoea, cough and fever, or an abnormal chest radiologic finding is observed, Lynparza treatment should be interrupted and prompt investigation initiated.
Danish: Hvis patienterne får nye eller forværrede respiratoriske symptomer, såsom dyspnø, hoste og feber, eller hvis der radiologisk observeres en abnormitet i brystet, bør behandling med Lynparza afbrydes, og der bør omgående igangsættes en undersøgelse.
English: At 24 and 36 months, respectively, 68% and 45% patients remained in CR in the olaparib arm, and 34% and 22% of patients in the placebo arm.
Danish: Efter 24 og 36 måneder var henholdsvis 68 % og 45 % patienterne stadig i CR i olaparibarmen og 34 % og 22 % af patienterne i placeboarmen.
English: Treatment may be interrupted to manage adverse reactions such as nausea, vomiting, diarrhoea, and anaemia and dose reduction can be considered (see section 4.8).
Danish: Behandlingen kan afbrydes for at håndtere bivirkninger, såsom kvalme, opkastning, diarré og anæmi, og dosisreduktion kan overvejes (se pkt.
English: Patients should not start treatment with Lynparza until they have recovered from haematological toxicity caused by previous anticancer therapy (haemoglobin, platelet and neutrophil levels should be ≤CTCAE grade 1).
Danish: Behandling med Lynparza bør ikke indledes, før patienten er kommet sig over hæmatologisk toksicitet, som skyldes tidligere anticancerbehandling (hæmoglobin-, trombocyt- og neutrofilniveauet bør være ≤CTCAE grad 1).
English: • pimozide, quetiapine - used to treat mental health problems
Danish: • pimozid, quetiapin - anvendes til behandling af psykiske lidelser
English: In BRCA-deficient in vivo models, olaparib given after platinum treatment resulted in a delay in tumour progression and an increase in overall survival compared to platinum treatment alone.
Danish: I BRCA-defekte in vivo-modeller resulterede olaparib givet efter platinbehandling i en forsinkelse i tumorprogression og en stigning i samlet overlevelse i sammenligning med platinbehandling alene.
English: Pre-planned subgroup analysis by BRCA-mutation status identified patients with BRCA-mutated ovarian cancer (n=136, 51.3%) as the subgroup that derived the greatest clinical benefit from olaparib maintenance monotherapy.
Danish: En forudplanlagt sub-gruppeanalyse af BRCA-mutationsstatus identificerede patienter med BRCA-muteret ovariecancer (n=136, 51,3 %), som den sub-gruppe, der fik den største kliniske fordel af vedligeholdelsesmonoterapi med olaparib.
English: In this study 391 patients were randomised 2:1 to receive either Lynparza (300 mg [2 x 150 mg tablets] twice daily) or placebo.
Danish: I dette studie blev 391 patienter randomiseret 2:1 til enten Lynparza (300 mg [2 x 150 mg tabletter] to gange dagligt) eller placebo.
English: Detection of BRCA mutation
Danish: Detektering af BRCA-mutation
English: Lynparza is contraindicated during breast-feeding and for 1 month after receiving the last dose, given the pharmacologic property of the product (see section 4.3).
Danish: Lynparza er kontraindiceret under amning og i 1 måned efter sidste dosis på grund af produktets farmakologiske egenskaber (se pkt.
English: Secondary efficacy endpoints included time from randomisation to second progression or death (PFS2), overall survival (OS), time from randomisation to discontinuation of treatment or death (TDT), time from randomisation to first subsequent anticancer therapy or death (TFST) and health related quality of life (HRQoL).
Danish: Sekundære endepunkter omfattede tid fra randomisering til anden progression eller død (PFS2), samlet overlevelse (OS), tid fra randomisering til seponering af behandlingen eller død (TDT), tid fra randomisering til første efterfølgende anticancerbehandling eller død (TFST) og helbredsrelateret livskvalitet (HRQoL).
English: What Lynparza contains
Danish: Lynparza indeholder
English: Proportion of patients event free
Danish: Andel af patienter uden hændelser
English: • indigestion or heartburn (dyspepsia)
Danish: • fordøjelsesbesvær eller halsbrand (dyspepsi)
English: After a number of rounds of replication, genomic instability can reach insupportable levels and result in cancer cell death, as cancer cells have a high DNA damage load relative to normal cells.
Danish: Efter et antal runder med replikation kan genomisk ustabilitet nå uoverskuelige niveauer og resultere i cancercelledød, da cancerceller har en høj DNA-skadebelastning i forhold til normale celler.
English: Adverse reactions that most commonly led to dose interruptions and/ or reductions were anaemia (13.9%), vomiting (7.1%), nausea (6.6%), fatigue/asthenia (6.1%) and neutropenia (5.8%).
Danish: De bivirkninger, der oftest medførte dosisafbrydelser og/eller dosisreduktioner var anæmi (13,9 %), opkastning (7,1 %), kvalme (6,6 %), træthed/asteni (6,1 %) og neutropeni (5,8 %).
English: Lynparza can be administered to patients with mild or moderate hepatic impairment (Child-Pugh classification A or B) with no dose adjustment (see section 5.2).
Danish: Lynparza kan administreres til patienter med let eller moderat nedsat leverfunktion (Child-Pugh klassifikation A eller B) uden dosisjustering (se pkt.
English: Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2mutations, who have HER2 negative locally advanced or metastatic breast cancer.
Danish: Lynparza er indiceret som monoterapi til behandling af voksne patienter med germline BRCA1/2mutationer, der har HER2-negativ lokal fremskreden eller metastatisk brystcancer.
English: They received an average of 3 previous chemotherapy regimens (range 2-11) and 2.6 previous platinum-containing chemotherapies (range 2-8).
Danish: De havde i gennemsnit modtaget 3 tidligere kemoterapibehandlinger (interval 2-11) og 2,6 tidligere platinholdige kemoterapibehandlinger (interval 2-8).
English: In vitro, olaparib produced little/no inhibition of UGT1A4, UGT1A9, UGT2B7, or CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 or 2E1 and is not expected to be a clinically significant time dependent inhibitor of any of these CYP enzymes.
Danish: In vitro hæmmede olaparib ikke eller i ringe grad UGT1A4, UGT1A9, UGT2B7, eller CYP 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 eller 2E1 og forventes ikke at være en klinisk signifikant tidsafhængig hæmmer af nogen af disse CYP-enzymer.
English: No olaparib or placebo-treated patients discontinued due to diarrhoea.
Danish: Ingen olaparib- eller placebobehandlede patienter seponerede behandlingen på grund af diarré.
English: Please note Lynparza is also available as a 50 mg capsule.
Danish: Bemærk, at Lynparza også findes som en 50 mg kapsel.
English: Distribution The in vitro protein binding is approximately 82% at clinically relevant concentrations of 10 µg/mL.
Danish: Fordeling In vitro-proteinbindingen er ca. 82 % ved klinisk relevante koncentrationer på 10 µg/ml.
English: Tell your doctor, pharmacist or nurse if you are taking or are planning to take any of the following medicines:
Danish: Fortæl det til din læge, apotekspersonalet eller sundhedspersonalet, hvis du tager eller planlægger at tage noget af følgende medicin:
English: Silica, colloidal anhydrous Mannitol
Danish: Silica, kolloid vandfri Mannitol
English: • Taking the wrong dose or a tablet instead of a capsule could lead to Lynparza not working properly or to more side effects.
Danish: • Hvis du tager den forkerte dosis eller en tablet i stedet for en kapsel, kan det betyde, at Lynparza ikke virker korrekt, eller at du får flere bivirkninger.
English: • Taking the wrong dose or a capsule instead of a tablet could lead to Lynparza not working properly or to more side effects.
Danish: • Hvis du tager den forkerte dosis eller en kapsel i stedet for en tablet, kan det betyde, at Lynparza ikke virker korrekt, eller at du får flere bivirkninger.
English: Previous taxane treatment in (neo)adjuvant setting metastatic setting
Danish: Tidligere behanding med taxan i (neo)adjuverende regi metastatisk regi
English: Patient-reported outcome (PRO) data indicate no difference for the olaparib-treated patients as compared to placebo as assessed by the change from baseline in the TOI of the FACT-O.
Danish: Resultater fra patientrapporterede oplysninger (PRO) indikerede ingen forskel mellem patienter behandlet med olaparib sammenlignet med placebo efter vurdering af ændringen fra baseline i TOI fra FACT-O.
English: There are no efficacy or safety data on maintenance retreatment with Lynparza following first or subsequent relapse in ovarian cancer patients or on retreatment of breast cancer patients (see section 5.1).
Danish: Der foreligger ingen data om effekt eller sikkerhed ved gentaget vedligeholdelsesbehandling med Lynparza ved første eller efterfølgende tilbagefald hos patienter med ovariecancer eller om genbehandling for patienter med brystcancer (se pkt.
English: Vomiting was reported early, with first onset within the first two months of Lynparza treatment in the majority of patients.
Danish: Opkastning blev rapporteret tidligt med første opståen inden for de første to måneder af behandlingen med Lynparza hos størstedelen af patienterne.
English: The most frequently observed adverse reactions across clinical trials in patients receiving Lynparza monotherapy (≥ 10%) were nausea, vomiting, diarrhoea, dyspepsia, fatigue, headache, dysgeusia, decreased appetite, dizziness, upper abdominal pain, cough, dyspnoea, anaemia, neutropenia, thrombocytopenia and leukopenia.
Danish: De hyppigst observerede bivirkninger i kliniske forsøg med patienter, som fik Lynparza-monoterapi (≥ 10 %), var kvalme, opkastning, diarré, dyspepsi, træthed, hovedpine, dysgeusi, nedsat appetit, svimmelhed, øvre abdominalsmerter, hoste, dyspnø, anæmi, neutropeni, trombocytopeni og leukopeni.
English: Median age was 59 years in both arms.
Danish: Medianalderen var 59 år i begge arme.
English: • ovarian cancer that has come back (recurred).
Danish: • kræft i æggestokkene, som er vendt tilbage.
English: Nausea events led to discontinuation in 2.3% of olaparib-treated patients (CTCAE Grade 2) and 0.8% of placebo-treated patients (CTCAE Grade 1); 0.8% and 0.4% of olaparib-treated patients discontinued treatment due to low grade (CTCAE Grade 2) vomiting and dyspepsia, respectively.
Danish: Kvalme medførte seponering hos 2,3 % af de olaparibbehandlede patienter (CTCAE grad 2) og 0,8 % af placebobehandlede patienter (CTCAE grad 1); 0,8 % og 0,4 % af de olaparibbehandlede patienter seponerede behandling på grund af lav grad (CTCAE grad 2) af henholdsvis opkastning og dyspepsi.
English: Lynparza monotherapy has been associated with adverse reactions generally of mild or moderate severity (CTCAE grade 1 or 2) and generally not requiring treatment discontinuation.
Danish: Lynparza-monoterapi er blevet forbundet med bivirkninger, som generelt var af let eller moderat sværhedsgrad (CTCAE grad 1 eller 2) og som generelt ikke kræver afbrydelse af behandlingen.
English: In the olaparib and placebo arms, 6% and 5% of patients had prior bevacizumab, respectively.
Danish: I olaparib- og placeboarmene havde henholdsvis 6 % og 5 % af patienterne tidligere modtaget bevacizumab.
English: It cannot be excluded that olaparib may increase the exposure to substrates of BCRP (e.g. methotrexate, rosuvastatin), OATP1B1 (e.g. bosentan, glibenclamide, repaglinide, statins and valsartan), OCT1 (e.g. metformin), OCT2 (e.g. serum creatinine), OAT3 (e.g. furosemide and methotrexate), MATE1 (e.g. metformin) and MATE2K (e.g. metformin).
Danish: Det kan ikke udelukkes, at olaparib kan øge eksponeringen af substrater for BCRP (fx methotrexat, rosuvastatin), OATP1B1 (fx bosentan, glibenclamid, repaglinid, statiner og valsartan), OCT1 (fx metformin), OCT2 (fx serumkreatinin), OAT3 (fx furosemid og methotrexat), MATE1 (fx metformin) og MATE2K (fx metformin).
English: Large rearrangements in the BRCA1/2 genes were detected in 7.4% (10/136) of the randomised patients.
Danish: Der blev opdaget større strukturelle ændringer i BRCA1/2 generne hos 7,4 % (10/136) af de randomiserede patienter.
English: Median age was 53 years in both arms.
Danish: Medianalder var 53 år i begge arme.
English: • a type of ovarian cancer (BRCA-mutated) that has responded to the first treatment with standard platinum-based chemotherapy.
Danish: • en type kræft i æggestokkene (BRCA-muteret), som har reageret på den første behandling med platinbaseret standardkemoterapi.
English: The following adverse reactions have been identified in clinical trials with patients receiving Lynparza monotherapy where patient exposure is known.
Danish: Følgende bivirkninger er blevet identificeret i kliniske studier med patienter, som fik Lynparza-monoterapi, hvor patienteksponeringen er kendt.
English: In population based PK analyses, patient age, bodyweight or race (including White and Japanese patients) were not significant covariates.
Danish: I populationsbaserede PK-analyser var patientens alder, legemsvægt eller race (herunder kaukasiske og japanske patienter) ikke signifikante covariater.
English: Patients must have confirmation of a deleterious or suspected deleterious breast cancer susceptibility gene (BRCA) mutation (either germline or tumour) before Lynparza treatment is initiated.
Danish: Det skal være bekræftet, at patienterne har en risikogivende eller formodet risikogivende mutation af et brystkræft modtageligt gen (BRCA) (enten germline eller tumor), inden behandling med Lynparza indledes.
English: At the time of the analysis of PFS the median duration of treatment was 8 months for olaparib and 4 months for placebo.
Danish: På tidspunktet for analysen af PFS var medianvarigheden af behandlingen 8 måneder for olaparib og 4 måneder for placebo.
English: First-line maintenance treatment of BRCA-mutated advanced ovarian cancer: SOLO1 Study
Danish: Førstelinjevedligeholdelsesbehandling af BRCA-muteret fremskreden ovariecancer: SOLO1-studiet
English: • Tablet core: copovidone, silica colloidal anhydrous, mannitol, sodium stearyl fumarate.
Danish: • Tabletkerne: copovidon, kolloid vandfri silica, mannitol, natriumstearylfumarat.
English: If you are planning to breast-feed, tell your doctor.
Danish: Hvis du har planer om at amme, skal du tale med lægen.
English: Patients with PR at study entry either achieved CR (15% in olaparib arm and 4% in the placebo arm at 24 months, remained in CR at 36 months) or had further PR/stable disease (43% in olaparib arm and 15% in the placebo arm at 24 months; 17% in olaparib arm and 15% in placebo arm at 36 months).
Danish: Patienter med PR ved indtræden i studiet opnåede enten CR (15 % i olaparibarmen og 4 % i placeboarmen efter 24 måneder, forblev i CR efter 36 måneder) eller havde yderligere PR/stabil sygdom (43 % i olaparibarmen og 15 % i placeboarmen efter 24 måneder; 17 % i olaparibarmen og 15 % i placeboarmen efter 36 måneder).
English: Secondary efficacy endpoints included OS, disease control rate (DCR) defined as confirmed CR/PR + SD (stable disease), HRQoL and disease related symptoms.
Danish: Sekundære effektendepunkter omfattede OS, sygdomskontrolrate (DCR) defineret som bekræftet CR/PR + SD (stabil sygdom), HRQoL og sygdomsrelaterede symptomer.
English: The magnitude of the effect of moderate to strong inducers (e.g. efavirenz, rifabutin) on olaparib exposure is not established, therefore the co-administration of Lynparza with these medicinal products is also not recommended (see section 4.4).
Danish: Størrelsesordenen af de moderate til stærke induktorers (fx efavirenz, rifabutin) effekt på olaparibs eksponering er ikke fastlagt, og derfor frarådes samtidig administration af Lynparza og disse lægemidler også (se pkt.
English: Median age was 56 years in both arms.
Danish: Medianalderen var 56 år i begge arme.
English: Haematological toxicity has been reported in patients treated with Lynparza, including clinical diagnoses and/or laboratory findings of generally mild or moderate (CTCAE grade 1 or 2) anaemia, neutropenia, thrombocytopenia and lymphopenia.
Danish: Der er rapporteret om hæmatologisk toksicitet hos patienter, som er behandlet med Lynparza, herunder kliniske diagnoser og/eller laboratoriefund af generelt let eller moderat (CTCAE grad 1 eller 2) anæmi, neutropeni, trombocytopeni og lymfopeni.
English: At the time of the analysis of PFS the median duration of treatment was 19.4 months for olaparib and 5.6 months for placebo.
Danish: På tidspunktet for analysen af PFS var medianvarigheden af behandlingen 19,4 måneder for olaparib og 5,6 måneder for placebo.
English: Male patients:
Danish: Mandlige patienter:
English: The analysis was performed using a Cox proportional hazards model including response to previous platinum chemotherapy (CR or PR) as a covariate.
Danish: Analysen blev udført med en Cox proportional hazards-model, der inkluderede respons på tidligere platinbaseret kemoterapi (CR eller PR) som kovariat.
English: This medicinal product contains 0.24 mg sodium per 100 mg tablet and 0.35 mg sodium per 150 mg tablet, i.e. essentially “sodium-free”.
Danish: Dette lægemiddel indeholder 0,24 mg natrium pr. 100 mg tablet og 0,35 mg natrium pr. 150 mg tablet, dvs. det er i det væsentlige natriumfrit.
English: BRCA mutation status should be determined by an experienced laboratory using a validated test method (see section 5.1).
Danish: BRCA-mutationsstatus bør fastslås af et erfarent laboratorium under anvendelse af en valideret testmetode (se pkt.
English: In rat embryofoetal development studies, and at dose levels that did not induce significant maternal toxicity, olaparib caused reduced embryofoetal survival, reduced foetal weight and foetal developmental abnormalities, including major eye malformations (e.g. anophthalmia, microphthalmia), vertebral/rib malformation and visceral and skeletal abnormalities.
Danish: I et studie af embryoføtal udvikling hos rotter og ved dosisniveauer, der ikke inducerede signifikant maternal toksicitet, forårsagede olaparib nedsat embryoføtal overlevelse, reduceret føtal vægt og føtale udviklingsanomalier, herunder svære øjenmisdannelser (fx anoftalmi, mikroftalmi), vertebrale/ribbensmisdannelser og viscerale og skeletale abnormiteter.
English: Patient-reported outcome (PRO) data indicate no difference for the olaparib-treated patients as compared to placebo as measured by improvement and worsening rates in the TOI and FACT-O total.
Danish: Resultater fra patientrapporterede oplysninger (PRO) indikerede ingen forskel mellem patienterne behandlet med olaparib sammenlignet med placebo målt ved forbedrings- og forværringsrater i TOI og FACT-O total.
English: The pharmacokinetics of olaparib at the 300 mg tablet dose are characterised by an apparent plasma clearance of ~7 L/h, an apparent volume of distribution of ~158 L and a terminal half-life of 15 hours.
Danish: Farmakokinetikken for olaparib ved en tabletdosis på 300 mg er kendetegnet ved en tilsyneladende plasmaclearance på ~7 l/time, et tilsyneladende distributionsvolumen på ~158 l og en terminal halveringstid på 15 timer.
English: In a post-hoc analysis of the subgroup of patients that had not progressed on chemotherapy other than platinum, the median PFS in the olaparib arm (n=22) was 8.3 months (95% CI 3.1-16.7) and 2.8 months (95% CI 1.4-4.2) in the chemotherapy arm (n=16) with a HR of 0.54 (95% CI 0.24-1.23).
Danish: I en post-hoc-analyse af subgruppen af patienter, der ikke havde udvist progression på ikke-platinholdig kemoterapi, var median PFS i olaparib-armen (n=22) 8,3 måneder (95 % CI 3,1-16,7) og 2,8 måneder (95 % CI 1,4-4,2) i kemoterapi-armen (n=16) med et HR på 0,54 (95 % CI 0,24-1,23).
English: In population based PK analyses, patient age, gender, bodyweight or race (including White and Japanese patients) were not significant covariates.
Danish: I populationsbaserede PK-analyser var patientens alder, køn, legemsvægt eller race (herunder ikkekaukasiske og japanske patienter) ikke signifikante covariater.
English: Patients could not have received prior olaparib or other PARP inhibitor treatment.
Danish: Patienterne måtte ikke tidligere have modtaget olaparib eller anden PARP-inhibitorbehandling.
English: If you are not sure, talk to your doctor, pharmacist or nurse before taking Lynparza.
Danish: Hvis du er i tvivl, skal du tale med lægen, apotekspersonalet eller sundhedspersonalet, inden du tager Lynparza.
English: There are no data on retreatment with Lynparza following subsequent relapse (see section 5.1).
Danish: Der eksisterer ingen data om gentagelse af behandling med Lynparza ved et efterfølgende tilbagefald (se pkt.
English: AstraZeneca UK Limited Silk Road Business Park Macclesfield Cheshire
Danish: AstraZeneca UK Ltd. Silk Road Business Park Macclesfield Cheshire
English: The majority of patients remained on the 300 mg bd starting dose of olaparib.
Danish: Størstedelen af patienterne forblev på startdosen 300 mg olaparib bd.
English: Keep doing so for as long as your doctor, pharmacist or nurse tells you to.
Danish: Bliv ved med det så længe din læge, apotekspersonalet eller sundhedspersonalet siger, du skal.